Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies.
作者信息
van Raalte Daniël H, Bjornstad Petter, Heerspink Hiddo J L, Persson Frederik, Cherney David Z I
机构信息
Diabetes Center, Internal Medicine, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands.
Department of Medicine, Division of Nephrology, University of Colorado School of Medicine, Aurora, Colorado, USA; Section of Endocrinology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
出版信息
Kidney Int. 2021 Mar;99(3):768-770. doi: 10.1016/j.kint.2020.12.006.
Abstract
摘要
相似文献
1
Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies.临床试验中标准化肾脏结局的重要性：以近期钠-葡萄糖协同转运蛋白2抑制剂研究为例
Kidney Int. 2021 Mar;99(3):768-770. doi: 10.1016/j.kint.2020.12.006.
2
Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor.钠-葡萄糖协同转运蛋白2抑制剂所致正常血糖性酮症酸中毒
Am J Ther. 2018 Sep/Oct;25(5):e590-e591. doi: 10.1097/MJT.0000000000000602.
3
Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.使用钠-葡萄糖协同转运蛋白2抑制剂治疗的2型糖尿病患者中的正常血糖性糖尿病酮症酸中毒
Can Fam Physician. 2016 Sep;62(9):722-4.
4
Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.钠-葡萄糖协同转运蛋白 2 抑制剂与 2 型糖尿病患者不良肾脏结局风险：一项随机对照试验的网络和累积荟萃分析。
Diabetes Obes Metab. 2017 Aug;19(8):1106-1115. doi: 10.1111/dom.12917. Epub 2017 Mar 31.
5
[Outcome studies on SGLT-2 inhibitors].[钠-葡萄糖协同转运蛋白2抑制剂的疗效研究]
Internist (Berl). 2019 Sep;60(9):903-911. doi: 10.1007/s00108-019-0656-x.
6
7
[Severe diabetic ketoacidosis, acute kidney injury and dehydration due to canagliflozin in type 2 diabetes mellitus patient: Atypical clinical presentation].[2型糖尿病患者因卡格列净导致严重糖尿病酮症酸中毒、急性肾损伤和脱水：非典型临床表现]
Aten Primaria. 2019 Dec;51(10):664-666. doi: 10.1016/j.aprim.2019.04.007. Epub 2019 Jul 17.
8
Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.卡格列净对2型糖尿病患者钠-葡萄糖协同转运蛋白2（SGLT2）的抑制作用
Cardiovasc Hematol Agents Med Chem. 2013 Sep;11(3):203-6. doi: 10.2174/187152571103140120103032.
9
Canagliflozin: A Review in Type 2 Diabetes.卡格列净：用于 2 型糖尿病的药物评价。
Drugs. 2017 Sep;77(14):1577-1592. doi: 10.1007/s40265-017-0801-6.
10
Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.SGLT2 抑制剂心血管安全性试验在真实世界中的可推广性：对临床实践的影响。
Adv Ther. 2019 Oct;36(10):2895-2909. doi: 10.1007/s12325-019-01043-z. Epub 2019 Aug 13.
引用本文的文献
1
Heterogeneity in the definition of major adverse kidney events: a scoping review.主要不良肾脏事件定义中的异质性：范围综述。
Intensive Care Med. 2024 Jul;50(7):1049-1063. doi: 10.1007/s00134-024-07480-x. Epub 2024 May 27.
2
Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial.在评估恩格列净疗效和安全性心血管结局（VERTIS CV）试验中，恩格列净对基线时心力衰竭患者肾脏结局的影响。
Kidney Int Rep. 2023 Jan 20;8(4):746-753. doi: 10.1016/j.ekir.2023.01.011. eCollection 2023 Apr.
3
Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A Analysis from the Randomized VERTIS CV Trial.恩格列净用于非白蛋白尿性糖尿病肾病患者的心脏和肾脏结局：来自随机VERTIS CV试验的分析
Kidney Int Rep. 2022 May 13;7(8):1782-1792. doi: 10.1016/j.ekir.2022.05.007. eCollection 2022 Aug.
4
Sodium-glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria.钠-葡萄糖协同转运蛋白2抑制剂：根据基线蛋白尿情况的肾脏结局
Clin Kidney J. 2021 Jun 11;14(12):2463-2471. doi: 10.1093/ckj/sfab096. eCollection 2021 Dec.
5
Transforming the Care of Patients with Diabetic Kidney Disease.将糖尿病肾病患者的护理转变。
Clin J Am Soc Nephrol. 2021 Oct;16(10):1590-1600. doi: 10.2215/CJN.18641120. Epub 2021 Jun 8.
本文引用的文献
1
International consensus definitions of clinical trial outcomes for kidney failure: 2020.2020年肾衰竭临床试验结果的国际共识定义。
Kidney Int. 2020 Oct;98(4):849-859. doi: 10.1016/j.kint.2020.07.013.
2
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.在 2 型糖尿病患者中使用依格列净的心血管结局。
N Engl J Med. 2020 Oct 8;383(15):1425-1435. doi: 10.1056/NEJMoa2004967. Epub 2020 Sep 23.
3
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.达格列净对 2 型糖尿病患者肾脏疾病发生和进展的影响：DECLARE-TIMI 58 随机试验分析。
Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617. doi: 10.1016/S2213-8587(19)30180-9. Epub 2019 Jun 10.
4
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.卡格列净与 2 型糖尿病患者的肾脏结局：CANVAS 项目随机临床试验的结果。
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.
5
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.恩格列净与 2 型糖尿病患者的肾脏疾病进展。
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
Zotero 插件